biospace med (www.biospacemed.com), an emerging medical technology company based in Paris, and Oldelft Benelux, a renowned specialist in medical diagnostic imaging, announced today the signature of an exclusive distribution agreement of EOS, the world’s first ultra-low-dose 2D|3D imager. The agreement will cover the distribution of EOS for the Benelux area (Belgium, The Netherlands & Luxembourg).
“The EOS system is a valuable asset to our product portfolio. The system fits seamlessly in our strategy to offer low-dose systems in a high-end market, especially since the discussion on dose and dose reduction have become more important again recently.”
“The installation of our ultra-low-dose EOS imager in the University Medical Center Groningen, one of the largest hospitals in The Netherlands, has clearly demonstrated the great interest of the Dutch medical community for our breakthrough technology. We are very enthusiastic about this agreement with a key player in the Benelux medical imaging field,” said Peter Cardle, biospace med’s Vice President of Sales.
“We are extremely pleased to announce this new distribution agreement, as it will help biospace med to penetrate exciting new markets in Europe,” said Marie Meynadier, Ph.D., chief executive officer of biospace med. “The recent progress we have made in new-site installations across the globe, combined with the clinical coverage in major congresses last year, is demonstrating that EOS is no longer a nice-to-have product but clearly a must-have, specifically in dose irradiation. EOS uses dramatically less radiation than a conventional x-ray or CT scan and thus represents an extraordinary enhancement in musculoskeletal imaging—as all other imaging modalities deliver a substantial dose of radiation to the patient,” added Dr. Meynadier.
“We are very pleased to have acquired the distributorship for EOS,” said Guido Geerts, Msc., managing director of Oldelft Benelux. “The EOS system is a valuable asset to our product portfolio. The system fits seamlessly in our strategy to offer low-dose systems in a high-end market, especially since the discussion on dose and dose reduction have become more important again recently.”